Immunophotonics has received a new U.S. patent that further strengthens the intellectual property protection surrounding its proprietary technology and lead clinical asset, IP-001.
The patent includes claims covering IP-001 in combination with immune-checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 therapies. These combination approaches represent an important area of interest in the evolving field of immuno-oncology. The patent also received a Patent Term Adjustment, extending its term into 2041.
As Immunophotonics continues advancing IP-001 through clinical development, expanding the company’s intellectual property portfolio supports the long-term value of its technology and its potential application in combination immunotherapy approaches.
